FDA Cites SmithKline Beecham For Misleading Bactroban Ad

Jan. 13, 2005
The FDA has cited SmithKline Beecham for disseminating misleading promotional materials for Bactroban Nasal, a product used to eradicate methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus is a bacterium that generally spreads in ...

The FDA has cited SmithKline Beecham for disseminating misleading promotional materials for Bactroban Nasal, a product used to eradicate methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus is a bacterium that generally spreads in hospitals, resulting in wound, pneumonia, respiratory, and urinary tract infections. Methicillin is a commonly used antibiotic to treat Staphylococcus infections. SmithKline made statements regarding the effectiveness of its product on a hospital display panel. These statements included: "Stop Methicillin Resistant Staphylococcus where they originate;" "Infection protection in a tube;" and "In a hospital study, Bactroban Nasal contributed to a dramatic reduction in MRSA infections and Vancomycin costs during an outbreak." Although these statements may be true, SmithKline failed to include information related to the drug's side effects, contraindications, and warnings, the FDA said. Under FDA regulations, "Promotional materials must present information relating to side effects, contraindications, and warnings with a prominence and readability reasonably comparable with any presentation of information relating to the use or efficacy of the drug." SmithKline must now immediately discontinue the use of this and any other similar promotional materials or face possible regulatory action, the agency said.

Popular Sponsored Recommendations

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

3D Printing a More Efficient Factory Floor

Nov. 16, 2023
Today’s additive manufacturing platforms make it simple to print a wide range of high-performing industrial parts as soon as possible and right where you need them — unlocking...

Beat the odds. Optimize product costs. Mitigate supply chain issues.

Sept. 12, 2023
Leverage fact-based supplier negotiations. Enhance design. Get to market faster. Our comprehensive Should Cost Analysis guide shows you how.

7 Crucial Steps to Improve Your OT Security

Oct. 23, 2023
Enhance OT security in manufacturing and production. Uncover the crucial steps to safeguard your operational technology. Protect against evolving threats and bridge the IT-OT ...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!